Scivanta Medical Corporation (OTC Bulletin Board: SCVM.OB) recently announced the results of its initial clinical trial for the Scivanta Cardiac Monitoring System (SCMS)

 Email Article |  Twitter |  Facebook |   Google Buzz |  digg it |   delicious |   StumbleUpon |   LinkedIn |   Technorati |  reddit 

civanta Medical Corporation (OTC Bulletin Board: SCVM.OB) recently announced the results of its initial clinical trial for the Scivanta Cardiac Monitoring System (SCMS) performed at Kaleida Health/Millard Fillmore Hospital in Buffalo, New York. SCMS was formerly known as the Hickey Cardiac Monitoring System, and it is an innovative cardiac monitoring system that utilizes a two-balloon esophageal catheter to monitor cardiac performance. The current standard of care for monitoring critically ill patients suffering from various cardiovascular conditions is an invasive procedure known as pulmonary artery catheterization. That procedure requires an incision into a patient's neck or groin and the insertion of a Swan-Ganz catheter into the right atrium, the ventricle of the heart, and the pulmonary artery. That procedure must be performed in an intensive care unit. Unlike the Swan-Ganz catheter, the SCMS will provide the primary measurements of cardiac performance in a minimally invasive and more cost effective manner. It is designed to be used outside of the costly overhead of an intensive care setting.

Richard Berger, M.D., a professor of clinical cardiology at the University of Miami Miller School of Medicine and a fellow of the American College of Cardiology, stated in the Company's press release, "Scivanta has conducted an initial clinical trial using a new technique to gather sophisticated, difficult to obtain cardiac hemodynamic information.  If the planned subsequent studies confirm the reliability of this technique, physicians will have readily available information that will surely impact positively on the treatment of numerous cardiac and non cardiac patients.  This information will be attainable with minimal risk due to the SCMS's relatively non invasive technique.  I believe that the SCMS would fit readily into the physician's office, the intensive care unit, the operating room and in all hemodynamic laboratories."

SCMS is expected to provide the primary measurements of cardiac performance in a minimally invasive and cost-effective manner. As medicine moves farther away from the cost associated with hospitals and ICU's, the SCMS would appear to have real potential both clinically and economically. Market opportunities for the SCMS include anesthesiologists in surgical settings where patients have risks of cardiac events, emergency room departments, out-patient and in-office monitoring of cardiac patients, and in-hospital monitoring of cardiac-challenged patients.

SCMS also has some distinct, patent-protected advantages over existing technologies:

• It can monitor the patient anywhere, as the patient is not restricted to ICU;
• It can monitor the patient anytime: does not need to be removed for eating, drinking or sleeping;
• Nurses can rapidly insert and position the SCMS, reducing medical expenses;
• It has a low-cost disposable catheter which should create a recurring sales model.